Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Mais filtros

Base de dados
Intervalo de ano de publicação
Int Immunopharmacol ; 79: 106088, 2020 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-31896512


Lung cancer is the leading cause of cancer deaths worldwide, mainly because it is usually in the advanced stage at the time of diagnosis. Although great progress has been made in the diagnosis and treatment of lung cancer in the past 25 years, the prognosis of lung cancer patients remains unsatisfactory. Agents targeting immune checkpoints have shown potential to improve therapeutic outcomes in patients with lung cancer. Inhibitors of PD-1/PD-L1 have been approved for the treatment of different types of lung cancer by FDA. Nevertheless, with the increasing number of clinical trails, the adverse events have emerged. Therefore, attention has been paid to finding out the factors influencing the therapeutic effect of anti-PD-1/PD-L1 therapy and reducing the occurrence of adverse events. Combination therapy may be an effective strategy to reduce the adverse events and improve the therapeutic effect. In this review, we summarized the current status and progress of anti-PD1/PD-L1 agents in lung cancer treatment.

Food Chem ; 305: 125435, 2020 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-31494497


Soluble dietary fibre (SDF) of micronized and non-micronized powders of lotus root nodes were investigated based on its adsorption and activity inhibition of pancreatic lipase (PL) by using circular dichroism, fluorescence spectroscopy and modification. Results showed that SDF2 (SDF from micronized powders of lotus root nodes) had stronger PL adsorption and enzyme activity inhibition than SDF1 (SDF from non-micronized powders of lotus root nodes). Specifically, SDF2 showed more binding sites than SDF1 in PL. There were hydrogen bonds and van der Waals interactions between SDF and PL, with Trp on PL probably serving as the main binding site. Carboxyl groups exhibited a stronger inhibition on PL by carboxymethyl and hydroxypropyl modification. The common mechanisms between SDF1 and SDF2 can be attributed to the combination between Trp and carboxyl groups, while the differences may be generated by the variations in structures or chemical groups induced by micronization.

Fibras na Dieta , Lipase/metabolismo , Metabolismo dos Lipídeos , Lotus/química , Adsorção , Hidrólise , Preparações de Plantas/química , Raízes de Plantas/química , Pós/química , Solubilidade
Int Immunopharmacol ; 74: 105695, 2019 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-31254958


NK cells may have great potential in tumor immunotherapy because they can kill tumor cells directly and quickly. Chimeric antigen receptor is a fusion protein composed of extracellular antigen recognition domain, transmembrane domain and intracellular signal domain. Rapid development of CAR-modified T cells has made tremendous achievements in the treatment of malignancies, especially hematological malignancies. However, there are many deficiencies in clinical application of CAR-T cell therapy. Car-modified NK cells have attracted much attention because they may avoid these shortcomings. At present, preclinical and clinical studies have shown that CAR-NK cell therapy may play significant anti-tumor role and it is safer than CAR-T cell therapy. Nevertheless, CAR-NK cell therapy still faces some challenges, such as the expansion and activation of primary NK cells in vitro, the difficulty to store and ship NK cell products and the low transduction efficiency. Thus further research is still needed to optimize CAR-NK cell therapy. Building better CAR-NK cells is important to improve the treatment efficacy and combination therapy offers a novel direction of NK-cell based immunotherapy.

Imunoterapia Adotiva/tendências , Células Matadoras Naturais/imunologia , Neoplasias/terapia , Receptores de Antígenos Quiméricos/genética , Animais , Proliferação de Células , Terapia Combinada , Humanos , Células Matadoras Naturais/transplante , Ativação Linfocitária , Neoplasias/imunologia
Int Immunopharmacol ; 70: 498-503, 2019 May.
Artigo em Inglês | MEDLINE | ID: mdl-30875561


Chimeric antigen receptor T (CAR-T) cell therapy provides possibility for the treatment of malignancies since clinical trials have shown that CAR-T therapy has a significant anti-tumor effect. Although many efforts have been made to improve the efficacy and reduce the side effects of CAR-T therapy, there are still many problems to solve. With the rapid development of this field, combination immunotherapy has been proved to improve the efficacy of CAR-T therapy. Studies have shown that radiotherapy, chemotherapy, oncolytic virotherapy, BTK inhibitors and immune checkpoint blockade-based therapy may further enhance the efficacy of CAR-T therapy while CRISPR/Cas9 technology and IL-1 blockade may improve the safety. In this review, we summarized the advantages and the mechanisms of the combination immunotherapy based on CAR-T cell therapy.

Antineoplásicos/uso terapêutico , Imunoterapia/métodos , Neoplasias/terapia , Receptores de Antígenos Quiméricos/genética , Linfócitos T/fisiologia , Animais , Anticorpos Monoclonais/uso terapêutico , Repetições Palindrômicas Curtas Agrupadas e Regularmente Espaçadas , Terapia Combinada , Receptores Coestimuladores e Inibidores de Linfócitos T/imunologia , Humanos , Interleucina-1/antagonistas & inibidores , Neoplasias/imunologia , Terapia Viral Oncolítica , Inibidores de Proteínas Quinases/uso terapêutico , Radioimunoterapia , Linfócitos T/transplante